ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?

The latest development is expected to bolster the company's Diabetes Care business. ABT Stock's Likely Trend Following the News Following the announcement, Abbott's shares moved down slightly 0.2%, finishing at $133.36 on Tuesday. On a positive note, Abbott's Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose ...